AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca recently completed a clinical study titled A Randomized, Double-blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared With Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants. The study aimed to evaluate the impact of different inhaler propellants on mucociliary clearance, a critical function in respiratory health.
Intervention/Treatment: The study tested two types of propellants used in metered dose inhalers (MDIs): HFO-1234ze(E) as the experimental treatment and HFA-134a as the reference. Both were administered via oral inhalation to assess their effects on mucociliary clearance.
Study Design: This was a randomized, double-blind, two-way crossover study involving healthy participants. Participants received both treatments in different sequences, with a washout period in between. The study was designed to ensure unbiased results by masking participants, care providers, and investigators.
Study Timeline: The study began on June 14, 2023, and was completed with the last update submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The completion of this study may influence AstraZeneca’s stock performance as it could lead to advancements in inhaler technology, potentially offering a competitive edge in the respiratory treatment market. Investors will be keenly observing any resulting product developments or regulatory approvals.
The study is completed, and further details are available on the ClinicalTrials portal.